Adaptive Biotech (ADPT) Earnings Call Transcript
Image source: The Motley Fool.DateFeb. 5, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Chad RobinsChief Financial Officer —…
9,675€
-2,27%
Echtzeit-Aktienkurs NeoGenomics
Bid:
Ask:
Nachrichten zur NeoGenomics Aktie
NeoGenomics: Distribution Moat In Community Oncology
…
Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves
Insiders have been trading these 5 stocks: (($GH)), (($JBL)), (($NEO)), (($DRI)) and (($CRMD)). Here is a breakdown of their recent…
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
Neogenomics EVP Olivo sells $250k in NEO stock By Investing.com
Neogenomics EVP Olivo sells $250k in NEO stock…
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of +50.00% and +2.27%, respectively, for the quarter ended September 2025. Do the…
NeoGenomics: Auf Erholungskurs dank neuem Flüssigbiopsietest und Patentsieg
Die Aktie des Anbieters von onkologischen Diagnostiktests und Beratungsdienstleistungen befand sich nach einer mehrjährigen Seitwärtsbewegung ab Ende 2024 im steilen…
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after news of a new government prescription drug policy…
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a…
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after news of a new government prescription drug policy…
Down 29.2% in 4 Weeks, Heres Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong…
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know
What Happened?
A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%)…
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%)…
NeoGenomics stock tumbles on weak EPS guidance By Investing.com
NeoGenomics stock tumbles on weak EPS guidance…
NeoGenomics (NEO) Tops Q4 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 100% and 0.92%, respectively, for the quarter ended December 2024. Do the…
NeoGenomics CEO steps down, shares fall 17% By Investing.com
NeoGenomics CEO steps down, shares fall 17%…
NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
…
NeoGenomics, Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Injunction against NeoGenomics over RaDaR assay affirmed by appeals court
…
Global Bioinformatics Services Market Size To Worth USD 12.71 Billion By 2033 | CAGR Of 14.40%
The Global Bioinformatics Services Market Size was Valued at USD 3.31 Billion in 2023 and the Worldwide Bioinformatics Services Market…
Earnings call: NeoGenomics sees 14% revenue growth in Q1 2024 By Investing.com
Earnings call: NeoGenomics sees 14% revenue growth in Q1 2024…
NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript
…
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after…